Active Ingredient History
Daclatasvir (BMS-790052) is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 3 infection. Daclatasvir prevents RNA replication and virion assembly by binding to NS5A, a nonstructural phosphoprotein encoded by HCV. Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly. NCATS
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Carcinoma, Hepatocellular (Phase 3)
COVID-19 (Phase 4)
Diabetes Mellitus (Phase 1)
Drug Interactions (Phase 1)
Drug Misuse (Phase 4)
Fibrosis (Phase 4)
Healthy Volunteers (Phase 1)
Hepacivirus (Phase 3)
Hepatic Insufficiency (Phase 1)
Hepatitis B (Phase 2/Phase 3)
Hepatitis C (Phase 4)
Hepatitis C, Chronic (Phase 4)
Hepatitis, Chronic (Phase 2)
HIV (Phase 3)
HIV Infections (Phase 2)
Infertility, Male (Phase 2/Phase 3)
Insulin Resistance (Phase 4)
Kidney Failure, Chronic (Phase 4)
Liver Diseases (Phase 1)
Liver Transplantation (Phase 4)
Metabolic Syndrome (Phase 2/Phase 3)
Renal Insufficiency (Phase 4)
Severe Acute Respiratory Syndrome (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue